Elsevier

Medicina Clínica

Volume 142, Issue 5, 4 March 2014, Page 234
Medicina Clínica

Imagen de la semana
Poliosis secundaria al tratamiento con ipilimumabIpilimumab-induced poliosis

https://doi.org/10.1016/j.medcli.2013.07.005Get rights and content

References (0)

Cited by (1)

  • Adverse Hair Reactions to New Targeted Therapies for Cancer

    2019, Actas Dermo-Sifiliograficas
    Citation Excerpt :

    In the case of ipilimumab, the onset of vitiligo-like hypopigmentation is common (particularly in patients with melanoma), and in initial studies, up to 14% of patients experienced hypopigmentation of hair of the scalp, eyebrows, or eye lashes.18,19 Subsequently, there have been 2 reports of poliosis with this class of drugs, 1 with ipilimumab20 and the other with pembrolizumab.21 However, the reverse effect seems more frequent with PD-1/PD-L1 inhibitors, as a series of 14 patients was recently published of scalp repigmentation after receiving treatment with 1 of these PD-1/PD-L1 agents for nonsmall cell lung cancer (Fig. 3).22

View full text